Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ: ATAI )

1.530 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week
The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD. 
Via Talk Markets
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
Via Benzinga
Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
Psychedelic stocks have been making big moves beneath the surface, and the sector's popularity might spark again in 2024. 
Via InvestorPlace
3 Big New Catalysts for Psychedelics Stocks in 2024
This could be the year that psychedelics stocks start to fly. 
Via The Motley Fool
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury 
Via Benzinga
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub 
Via Benzinga
Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment
Biopharma company Atai Life Sciences (NASDAQ: ATAI) shared positive results from a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, under development for the potential treatment of PTSD. 
Via Benzinga
Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development
Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration... 
Via Benzinga
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
From atai Life Sciences
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From January 1, 2024
Via Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
Via Benzinga
Psychedelic Drug Stocks Index Up In December; Down YTD
The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021. 
Via Talk Markets
5 Biotech stocks tapping into unmet mental health treatment needs
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments. 
Via MarketBeat
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
Biden To Decide On Psychedelic Therapy Bill 
Via Benzinga
Psychedelic Drug Stocks Index Declined 1.6% This Week
Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD. 
Via Talk Markets
Topics ETFs
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy 
Via Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week
The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week. 
Via Talk Markets
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Defense Dept. Funds Ketamine Study For PTSD Treatment  
Via Benzinga
November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex
The 5 constituents in the Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months but jumped 30% in November. 
Via Talk Markets
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan 
Via Benzinga
Topics Cannabis
Exposures Cannabis
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
GH Research Drags Down Psychedelic Drug Stocks Index By 7%
The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week. 
Via Talk Markets
Insiders Buying Taysha Gene Therapies And 3 Other Stocks Under $2
The Dow Jones closed higher by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Atai Life Sciences' Q3 Earnings: Near $20M Burned QoQ, Says Funding 'Sufficient' To Streamline 2026
Clinical-stage psychedelics company atai Life Sciences (NASDAQ: ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023.  In numbers: 
Via Benzinga
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
From atai Life Sciences
Via GlobeNewswire
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart
Our Psychedelic Drug Stocks Index continues to exhibit extreme volatility, declining 8% this week, jumping 22% the previous week and falling 6.5% the week before that. This week's decline is based on... 
Via Talk Markets
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court 
Via Benzinga
Topics Economy
Exposures Interest Rates
Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22%
The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are ranked below in descending order as to their performances last week along with any pertinent news affecting their performances. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.